Skip to main content
Erschienen in: Supportive Care in Cancer 3/2023

01.03.2023 | Research

Palliative care use and utilization determinants among patients treated for advanced stage lung cancer care in the community and academic medical setting

verfasst von: Laurie E. McLouth, Tia Borger, Vilma Bursac, Michael Hoerger, Jessica McFarlin, Shaylla Shelton, Brent Shelton, Andrew Shearer, Marc T. Kiviniemi, Jerod L. Stapleton, Timothy Mullett, Jamie L. Studts, David Goebel, Ravneet Thind, Laura Trice, Nancy E. Schoenberg

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite clinical guidelines, palliative care is underutilized during advanced stage lung cancer treatment. To inform interventions to increase its use, patient-level barriers and facilitators (i.e., determinants) need to be characterized, especially among patients living in rural areas or those receiving treatment outside academic medical centers.

Methods

Between 2020 and 2021, advanced stage lung cancer patients (n = 77; 62% rural; 58% receiving care in the community) completed a one-time survey assessing palliative care use and its determinants. Univariate and bivariate analyses described palliative care use and determinants and compared scores by patient demographic (e.g., rural vs. urban) and treatment setting (e.g., community vs. academic medical center) factors.

Results

Roughly half said they had never met with a palliative care doctor (49.4%) or nurse (58.4%) as part of cancer care. Only 18% said they knew what palliative care was and could explain it; 17% thought it was the same as hospice. After palliative care was distinguished from hospice, the most frequently cited reasons patients stated they would not seek palliative care were uncertainty about what it would offer (65%), concerns about insurance coverage (63%), difficulty attending multiple appointments (60%), and lack of discussion with an oncologist (59%). The most common reasons patients stated they would seek palliative care were a desire to control pain (62%), oncologist recommendation (58%), and coping support for family and friends (55%).

Conclusion

Interventions should address knowledge and misconceptions, assess care needs, and facilitate communication between patients and oncologists about palliative care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33CrossRefPubMed Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33CrossRefPubMed
2.
Zurück zum Zitat Vijayvergia N, Shah PC, Denlinger CS (2015) “Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward,” (in eng). J Natl Compr Cancer Netw JNCCN 13(9):1151–1161CrossRefPubMed Vijayvergia N, Shah PC, Denlinger CS (2015) “Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward,” (in eng). J Natl Compr Cancer Netw JNCCN 13(9):1151–1161CrossRefPubMed
3.
Zurück zum Zitat LeBlanc TW, Nickolich M, Rushing CN, Samsa GP, Locke SC, Abernethy AP (2015) What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. Support Care Cancer J Article 23(12):3455–3463. https://doi.org/10.1007/s00520-015-2699-4CrossRef LeBlanc TW, Nickolich M, Rushing CN, Samsa GP, Locke SC, Abernethy AP (2015) What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. Support Care Cancer J Article 23(12):3455–3463. https://​doi.​org/​10.​1007/​s00520-015-2699-4CrossRef
4.
Zurück zum Zitat Bakitas MA et al (2015) Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33(13):1438CrossRefPubMedPubMedCentral Bakitas MA et al (2015) Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33(13):1438CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Bakitas M et al (2009) Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 302(7):741–749CrossRefPubMedPubMedCentral Bakitas M et al (2009) Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 302(7):741–749CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Beasley A, Bakitas MA, Edwards R, Kavalieratos D (2018) Models of non-hospice palliative care: a review. Ann Palliat Med 8(Suppl 1):S15–S21PubMed Beasley A, Bakitas MA, Edwards R, Kavalieratos D (2018) Models of non-hospice palliative care: a review. Ann Palliat Med 8(Suppl 1):S15–S21PubMed
Metadaten
Titel
Palliative care use and utilization determinants among patients treated for advanced stage lung cancer care in the community and academic medical setting
verfasst von
Laurie E. McLouth
Tia Borger
Vilma Bursac
Michael Hoerger
Jessica McFarlin
Shaylla Shelton
Brent Shelton
Andrew Shearer
Marc T. Kiviniemi
Jerod L. Stapleton
Timothy Mullett
Jamie L. Studts
David Goebel
Ravneet Thind
Laura Trice
Nancy E. Schoenberg
Publikationsdatum
01.03.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-023-07649-y

Weitere Artikel der Ausgabe 3/2023

Supportive Care in Cancer 3/2023 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.